| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6072400 | Journal of the American Academy of Dermatology | 2014 | 7 Pages |
Abstract
Treatment of indolent PCBCL with subcutaneously injected interferon-alfa demonstrated good response rates and tolerability. Response was not dose dependent. Relapses were observed in nearly all responding patients raising the question of interferon-alfa maintenance therapy in PCBCL.
Keywords
EORTCPrimary cutaneous marginal zone B-cell lymphomaPCBCLPCFCLPCMZLInterferon-alfaSystemic treatmentcomplete remissionEuropean Organization for Research and Treatment of CancerAdverse eventsprimary cutaneous B-cell lymphomamarginal zone B-cell lymphomafollicle center lymphomaprimary cutaneous follicle center lymphoma
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Staffan MD, Dorothea MD, Daniel MD, Marc MD,